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Program and Policy Considerations for
Tenofovir Gel in India: An Overview

India’s strong commitment and capacity to address the HIV epidemic contributed to a more
than 50 percent decline in new HIV infections
from 2000 to 2009 (UNAIDS 2012). The initial
response focused on awareness generation
and preventing HIV acquisition in the general
population. As data and experience led to
a deeper understanding of the epidemic, a
targeted approach has emphasised containing
HIV transmission from high-risk groups to the
general population. Importantly, India has also
provided a growing programme of treatment
and care for people living with HIV.
Globally and in India, women face significant
social and economic vulnerability to HIV. Currently, women constitute more than one-third
(39 percent) of the HIV-positive population in
India (NIMS/NACO 2012), and many more are
vulnerable to acquiring HIV and other sexually
transmitted infections (STIs). Overall women
have lower social status than men, and many
women have little or no capacity to control or
make decisions about their sexual lives. Men’s
risk-taking behaviour increases women’s HIV
risk.

An effective female-controlled HIV-prevention
method could mitigate women’s risk. Renewed
interest and new designs for female condoms
are slowly improving access; efforts in India
are focused primarily on female sex workers.
Vaginal microbicides are another potential tool
that women could use to protect themselves
from HIV acquisition, and research to identify
an effective microbicide continues.
Indian researchers have actively collaborated
in global efforts to find an effective vaginal
microbicide, and clinical trials for several
candidate products have included sites in India
(Joshi et al. 2005; Joglekar et al. 2007; Van
Damme et al. 2008; Mehendale et al. 2012).
Tenofovir gel is the only candidate microbicide that has been shown to be effective in a
clinical trial, although results from tenofovir gel
trials have been mixed. The CAPRISA 004 trial
in South Africa showed a 39 percent reduction
in women’s risk of HIV infection compared
with a placebo, providing the first clinical
evidence that a vaginal gel can be effective in
HIV prevention (Abdool Karim 2010). Women
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ward comprehensive prevention and integrated services
suggests that tenofovir gel could potentially be incorporated into the health system and provided to different user
groups.

The HIV Epidemic in India
The 2011 national sentinel surveillance estimated that
1.9 million people in India aged 15 and older were living
with HIV (NIMS/NACO 2012). An estimated 39 percent
are women. This represents a decline in the total number
of people living with HIV (PLHIV) and prevalence of HIV in
the country (see Figure 1) (NACO 2012). This decline has
varied across states. Although HIV prevalence declined in
six high-prevalence states1 from 2007–2011, it increased
in 11 other states (NIMS/NACO 2012).2 Along with declining prevalence overall, there was also a downward trend
in incidence and AIDS-related deaths from 2000–2009
(see Figure 2). In 2011, there was a further marginal
decline in new infections (1.16 million) and AIDS-related
deaths (1.5 million) (NIMS/NACO 2012). The reduction in
deaths has been attributed to free antiretroviral treatment (ART) made available since 2004 (NACO 2012).

Number of PLHIV (Lakhs)

Given the urgent need for HIV-prevention options for
women, a number of efforts are underway to prepare for
introduction of tenofovir gel should it be shown effective. One of these is a Guide to assist policymakers and
programme managers in identifying the most strategic
opportunities for introducing tenofovir gel. The Guide
includes three related components: a landscape analysis; a discussion guide for key opinion leader interviews;
and a programme planning tool. The landscape analysis,
summarised in this programme brief,
reviews the epidemiologic context of
Figure 1 Trend of HIV prevalence in India (2004–2009)
the HIV epidemic, highlights key poli30
cies and programmes related to HIV,
and provides other information rele25
vant to potential introduction of tenofovir vaginal gel in India. It draws on a
20
desk review of peer-reviewed and grey
literature as well as interviews with key
15
decision-makers (Prabhughate, et al.
2014). The full report and annexes are
10
available at www.popcouncil.org.
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in the CAPRISA trial were counseled to use the gel before
and after sex. The VOICE trial tested daily tenofovir in
both oral pill and vaginal gel forms, as well as daily oral
Truvada; none of these three products showed an effect
in reducing the risk of HIV acquisition, likely due to low
adherence. (Marrazzo, et al. 2013). FACTS 001, a largescale trial under way in South Africa, is replicating the
same dosing strategy for tenofovir gel that was used in
the CAPRISA 004 trial. The results from the FACTS trial
will provide a clearer picture of tenofovir gel effectiveness.

The policy and programme review sum0.05
marised here underscores a generally
0.00
0
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2009
favorable environment for introducing
tenofovir gel in India, although the
Number of PLHIV (Lakhs)
Adult HIV Prevalence (%)
costs and benefits of such an effort
would need further consideration.
Source: Technical report on HIV estimations 2010
India has long been an early adopter
1
States where HIV prevalence declined between 2007 and 2011:
of innovations in health as well as in
Andhra Pradesh, Karnataka, Maharashtra, Manipur, Nagaland, and
other sectors. It has a robust and growing pharmaceutical
Tamil Nadu.
industry known for low-cost drug production and, increas2
States where HIV prevalence increased between 2007 and 2011:
Arunanachal Pradesh, Assam, Chandigarh, Chattisgarh, Delhi, Jammu
ingly, for research and development of new drugs. At the
and Kashmir, Jharkhand, Kerala, Odisha, Punjab, Tripura, and Uttarasame time the overall direction of HIV programming tokhand.
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Women’s Vulnerabilities and
Risks

26.5

3.0

26.0

2.5

25.5
2.0

25.0
24.5

1.5

24.0

1.0

23.5
0.5
0.0

23.0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Estimated number
of PLHIV (Lakhs)

Annual dealths

Source: Technical report on HIV estimations 2010

A variety of social and economic vulnerabilities place women at risk of HIV.
Female sex workers’ particular vulnerabilities are recognised in the NACP, with
concomitant programme responses.
While the NACP now identifies women
as a vulnerable population, many other
risk factors specific to women are not
addressed in the programme. These
include: young age at marriage; male
migration; men who have sex with
men and women; and intimate partner
violence.

Estimated number of PLHIV (Lakhs)

Annual new infections and deaths (Lakhs)

Figure 2 Trend of prevalence and incidence of HIV, and deaths due to
AIDS in India (2000–2009)
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Age at marriage. Many women in India
marry at a young age: 74 percent of
married women are married before
age 20 (IIPS and Macro International
2007). In some states,3 more than 50 percent of women
get married before age 18, the minimum legal age. The
young age of marriage corresponds with early sexual
intercourse, and with other social and health risks. Marriage and first sexual experience at an early age expose
women to a prolonged period of vulnerability to acquiring
HIV and other STIs from their husbands. Women married
as adolescents are also at increased risk of marital violence (see below) (Raj et al. 2010).

The main route of HIV transmission is unprotected sex
(87.4 percent heterosexual and 1.3 percent homosexual),
except in northeastern states where injection drug use
is the predominant route of transmission (NACO 2011a).
The epidemic is concentrated, as prevalence remains
high among specific high-risk groups (now often referred
to as most-at-risk populations), which include injection
drug users, men who have sex with men, and female sex
workers, and bridge populations of male migrants and
truckers (see Figure 3) (NACO 2012).
In 2009, prevalence among high-risk
Figure 3 HIV prevalence among HRGs in India (2008–2009)
groups was much higher than the
Women attending
national prevalence—9.2 percent in
antenatal clinics
injection drug users, 7.3 percent in
Long distance truckers
men who have sex with men, and 4.9
percent in female sex workers (UNAIDS
Single male migrants
2010).
In response, the National AIDS Control
Programme-III (NACP-III, 2007–2012)
emphasised targeted interventions for
prevention focused on high-risk groups
and bridge populations. These were
peer-led interventions implemented
through nongovernmental organizations (NGOs) and community-based
organizations (CBOs) supported and
monitored by government agencies.
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Source: HIV sentinel surveillance, 2008–2009
3
These states include: the northern states of Bihar, Chattisgarh,
Jharkhand, Madhya Pradesh, Rajasthan, Uttar Pradesh, and West Bengal, and the southern state of Andhra Pradesh.
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Male migration. Recent research regarding migration underscores that partner migration increases women’s risk
of acquiring HIV. A case-control study in seven districts
with high rates of out-migration among men found that
HIV prevalence was higher among women with migrant
husbands. Attributable risk for women associated with
male migration ranged from 32.7 percent to 56.9 percent
(Saggurti et al. 2012).
Men who have sex with men and women. Research
among men who have sex with men and women confirms
women’s increased risk of acquiring HIV. Studies with
men who have sex with men and women have shown that
women are at risk of HIV acquisition due to unprotected
sex or inconsistent condom use. (Phillips et al. 2010;
Dandona et al. 2004).
Intimate partner violence. Married women and female
sex workers experiencing physical or sexual intimate partner violence are at risk of acquiring and/or transmitting
HIV infection. Violence or fear of violence may limit women’s ability to exercise choice in sexual activity and/or
condom use. In the 2006 National Family Health Survey
(NFHS), more than one-third of married women reported
physical intimate partner violence from their husbands
(IIPS and Macro International 2007). Those women
experiencing both physical and sexual IPV were four times
more likely to have HIV than women not experiencing
intimate partner violence (Silverman et al. 2008). Female
sex workers are also vulnerable to intimate partner
violence, with a number of implications for their sexual
and reproductive health. Female sex workers experiencing intimate partner violence are at greater risk of HIV
acquisition due to inconsistent condom use and a range
of other reproductive health problems, including pregnancy, pregnancy loss, and forced termination of pregnancy
(Swain et al. 2011; Deering et al. 2011).

Key Health Issues and Implications for
Tenofovir Gel
Contraception and dual protection. The overall contraceptive prevalence rate in India is 56 percent (IIPS and
Macro International 2007) and the vast majority of those
using contraception use modern methods: condoms,
injectables, intrauterine devices, male and female sterilization, pills. Importantly, female sterilization accounts
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for two-thirds of total contraceptive use and 77 percent
of modern method use (IIPS and Macro International
2007). The widespread use of female sterilization as a
family planning method can compromise women’s ability
to negotiate condom use. Husbands of sterilised women
are not likely to perceive the need for using any contraceptive method, and in India there is little knowledge and
awareness about the use of condoms as a “dual protection” method for family planning and HIV prevention. This
underscores the need for a woman-controlled HIV-prevention method like tenofovir gel.
Maternal health. The maternal mortality rate (MMR) has
been declining across all the regions of India in the past
decade, but this decline has been uneven. Although MMR
has declined in the Empowered Action Group states,4 it
remains high (308 as of 2009). In contrast, the southern
states’5 lower MMR of 127 as of 2009 provides hope of
achieving the Millennium Development Goal target of 109
(Office of Registrar General, India 2011).
STIs and reproductive tract infections (RTIs). A 2009
National AIDS Control Organization (NACO)-led review and
analysis found variation in the rates of STIs/RTIs (NACO
2009) and a considerable burden of STIs among women.
HSV2 seropositivity (IgG) was somewhat higher in women
compared to men in the general population (NACO 2009).
Women’s vulnerability and increased HIV risk is evidenced in the epidemiology of HIV as well as indicators of
family planning and maternal health. A woman-controlled
HIV- prevention product such as tenofovir gel that women
can access and use would be of value in mitigating this
risk.

Policy Environment
Soon after identification of the first HIV case in India in
1986, the national government responded with policies and
well-structured initiatives focused on generating data and
designing programmes to address the emerging patterns

4
The Empowered Action Group states are: Assam, Bihar, Chattisgarh,
Jharkhand, Madhya Pradesh, Odisha, Rajasthan, Uttar Pradesh, and
Uttarakhand.
5
The southern states referred to above are: Andhra Pradesh, Karnataka,
Kerala, Tamil Nadu.

of the HIV epidemic in the country (NACPP 2002).6 Each
initiative had specific objectives and strategies (NACO 2002;
NACO and Ministry of Health and Family Welfare 2006). As
the national programme evolved over the last two decades,
NACO has developed several policy and operational guidelines, which are updated periodically and available at http://
nacoonline.org/About_NACO/Policy_Guidelines/Policies_
Guidelines1.
Since 2002, the National AIDS Control and Prevention
Policy (NACPP) has provided overall direction and guidance for HIV and AIDS programming (NACPP 2002). The
NACPP underscores the government’s commitment to
HIV prevention and emphasises the responsibility of both
public and private entities. It recommends decentralization of the HIV and AIDS control programme and supports
integration into other national programmes. The NACPP
seeks to decrease vulnerability to HIV among key groups
including women and children. It underscores the need
to provide health care to HIV-positive people and reduce
stigma and discrimination. Strategies include promoting
HIV knowledge and safe behavioural practices among students, youth, and other sexually active populations, and
voluntary blood donation to ensure safe blood supply.
The public, nongovernmental, and private sectors are
involved in providing care, support, and treatment as well
as preventive services. The public sector has been the
main provider of preventive services, while the government is receptive to the involvement of the private and
nongovernmental sectors. The government provides a
conducive environment for national and international
NGOs to pilot programmatic innovations. It generally requires approval from NACO consistent with public sector
regulation of new initiatives. The public sector is generally
open to collaboration to determine how best to integrate
proven products and interventions into the public programme.

Programme and Strategy
The National AIDS Control Programme (NACP-III), operational from 2007-12, drew on lessons from earlier
programmes and on consultations with nongovernmental and community-based stakeholders. In contrast to
earlier programmes, it emphasised behaviour change
Programmes initiated included the Medium Term Plan (1990–92), the
first plan (NACP-I, 1992–99), second plan (NACP-II, 1999–2006), and
the NACP-III (2007–12).
6

rather than awareness generation, a more decentralised
response, and increased involvement of NGOs and
networks of people living with HIV. NACP-III aimed to halt
and reverse the epidemic by integrating prevention with
services providing care, support, and treatment.
Prevention. NACP-III’s primary focus was on prevention
given that that vast majority of people in India are HIV
negative. Accordingly, more than two-thirds of the total
resources were earmarked for prevention activities. The
programme adopted a three-pronged approach to reducing the overall epidemic which prioritised saturating highrisk groups and bridge populations with prevention messages (Ministry of Health and Family Welfare 2006). The
programme also aimed to address clients of sex workers
through providing condoms, social marketing campaigns,
and projects with men in occupational settings. Finally, it
prioritised outreach to high-risk groups in rural areas, and
to other highly vulnerable groups: children, youth aged
15–19, and women.
Prevention programmes were linked with care, support,
and treatment to ensure continuity of care. Specific
prevention services offered include targeted interventions
for high-risk groups and bridge populations, such as needle-syringe exchange and opioid substitution therapy for
injection drug users; prevention interventions for migrant
populations at source, transit, and destination settings;
and Link Worker Schemes7 for vulnerable populations
in rural areas. Broader programmes for both high-risk
groups and the general population include: prevention
and control of STIs/RTIs; blood safety; HIV counseling and
testing; prevention of parent-to-child transmission; condom promotion; and information, education, and communication, and behaviour change communication.
Care, support, and treatment. Care, support, and treatment programs offer a comprehensive set of services
despite commanding less than 20 percent of overall
programme resources. These include: laboratory services
for CD4 testing and other research, early infant diagnosis,
nutritional and psychological support through Community
Care Centres, drop-in centres for people living with HIV,
and coordinated HIV-TB services and treatment. The programme offers free first-line and second-line ART through
7
The Link Worker Scheme is an approach to identify and train a village-level workforce on issues of HIV/AIDS, gender, sexuality, and STIs,
who reach out to high risk groups and vulnerable populations in rural
areas.
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a range of service settings (see Figure 4) including pediatric ART and treatment of opportunistic
infections. Tenofovir oral tablets are included
in the regimen of first-line ART and provided
through the service delivery system.
Antiretroviral (ARV) service delivery. Access to
free ART, initiated in 2004 in six high-prevalence
states, has expanded rapidly, and second-line
therapy is now also available in a limited number
of ART Plus Centres. A structured service-delivery system aims to reduce loss-to-follow-up
and ensure continuity of care and access to the
entire spectrum of treatment, care, and support
services. NACP-IV, operational through 2017, emphasises scaling up access to ARVs and to treatment and prevention for opportunistic infections,
as well as strengthening linkages among relevant
service-delivery systems (NACO 2011b).

Figure 4 Structure of ART service provision
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Focus on women. Many national policies have acknowledged women’s vulnerability and HIV risk, and that it
derives from diverse factors that limit women’s access
to health services and control in sexual decision making.
Under NACP-III concerted efforts were made to mainstream HIV/AIDS interventions for women’s empowerment, and guidelines were developed to ensure gender-sensitive HIV interventions for both men and women
(NACO 2012).
The female condom programme, initiated in 2008, is now
in its second phase. This programme, focused mainly
on female sex workers, emphasises capacity building,
training, and behaviour change communication activities
to increase use of female condoms. After successful
implementation in four states,8 the programme has been
scaled up through a social marketing organization contracted by NACO.
Integration of HIV with other health services. Both the
NACP and Department of Health and Family Welfare
(DHFW) have addressed integration of HIV and sexual
and reproductive health. In 2010 a joint committee identified areas of convergence between NACO’s programmes
and India’s core programme on maternal health (Ministry
of Health and Family Welfare N.D.). The rationale was to
leverage the technical progress of the AIDS programme
managed by NACO and the extensive infrastructure of

the DHFW programmes. Areas identified for convergence
have included RTI/STI service provision, voluntary counseling and testing, prevention of parent-to-child transmission, and condom promotion. While operational issues
have limited implementation of the plan for convergence
(Ahsan 2011), several states highlight examples of successful integration.

Regulatory Environment
The Drug Controller General of India (DCGI) is the licensing authority that must approve the manufacture and/or
marketing of any new drug in India (Government of India).
A drug approved by the DCGI must be re-registered as a
new drug for each new route of administration (Central
Drugs Standard Control Organization)9. This means that
while tenofovir is approved by the DCGI as an oral tablet
and included in first-line ART treatment in the national
ART guidelines, the vaginal gel will need to be registered
as a new drug and for a new indication in the Indian
market.
The regulations for import of new drugs10 stipulate that
trials need to be carried out in India in accordance
with guidelines provided by the Central Drugs Standard
Control Organization (CDSCO)11. The DCGI can waive the
requirement for trials in India after considering data from
other countries. The DCGI may grant a waiver in consideration of the larger public interest, or if the new drug has
Rule 122-Eb of the Drugs and Cosmetics Act (CDSCO N.D.)
Rule 122-A of the Drugs and Cosmetics Act (CDSCO N.D.)
11
Schedule Y (Government of India 2005)
9

10
8

Andhra Pradesh, Maharashtra, Tamil Nadu, and West Bengal.
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been approved and marketed for several years in other
countries and the DCGI is satisfied that the published evidence regarding the drug’s safety is adequate. To register
a new drug, manufacturers have to submit an application
to the CDSCO as per the guideline for submitting a Common Technical Document (CDSCO 2011).

Financing
Currently, nearly all of the overall expenditure on health
in India comes from within the country, with an estimated
70–75 percent from the private sector, broadly defined.
Importantly, most of this is out-of-pocket expenditure by
individual consumers (WHO 2012). In contrast, the government’s HIV programme is largely funded by external
aid, with an estimated 69% of the most recent budget
for the NACP coming from external sources (NACO 2012).
At this time it is not clear whether tenofovir gel would be
financed through the public or private sectors or both, nor
what role external donors would play in financing procurement and delivery of tenofovir gel.

Partnerships
India’s commitment to building collective responsibility
for HIV and AIDS programmes is demonstrated in the
mainstreaming initiatives of NACO (NACO N.D.). Chaired
by the Prime Minister of India, NACO includes 31 ministries and departments in an effort to mainstream the programme at national and state levels. NACO also partners
with other sectors, including corporations and civil society
organizations. It has a number of ongoing partnerships
with community-based organizations and NGOs, especially those that provide targeted interventions to highrisk groups. Recognizing the importance and long-term
sustainability of these partnerships, NACO includes civil
society representatives in programme and policy development (NACO N.D.).
The most notable public–private partnership is the
targeted Condom Social Marketing Programme involving seven social marketing organizations in 13 states.
The programme has led to greater condom availability
for vulnerable populations. Other partnerships with the
private sector include workforce interventions in which
companies provide human resources and infrastructure
for ART centres for their employees while NACO supports
the cost of testing facilities and drugs for the community
(NACO N.D.).

Looking Ahead
India is at a critical juncture in the course of its HIV epidemic. Although the country’s national effort and focused
programming have begun to have an impact, many challenges remain and new ones are emerging. These include
the increase in prevalence in particular states and the
challenge of preventing transmission from bridge populations to the general population. The growing recognition
of the need to reduce HIV transmission through bridge
populations creates a potential for introducing tenofovir
gel, as it could be used by diverse women who are vulnerable to HIV infection.
The current prevention programme emphasises condom
promotion, and including female condoms among prevention options is relatively new. If tenofovir gel becomes
available, it could provide an additional option. Several
service delivery points could be used to offer tenofovir
gel to women if it is determined that it is appropriate and
cost-effective in India. The extensive coverage achieved
through targeted interventions for female sex workers
offers a potential opportunity for delivering tenofovir gel
in India. However, careful attention would be needed to
ensure that introducing tenofovir gel would not undermine successful condom promotion efforts. The tiered
service-delivery points in the ART structure may provide a
setting to offer tenofovir gel to women who test negative.
Tenofovir gel could also be offered to women at high risk
of HIV infection, such as partners of IDUs, male migrants,
and truckers at targeted service-delivery points.
The policy environment in the context NACP-IV provides
an important opportunity for promoting specific interventions that can empower women to manage their HIV
risk. Consultative meetings with stakeholders involved in
NACP-IV planning and implementation are an important
venue for targeted information about vaginal HIV-prevention products including tenofovir gel. Awareness generated through such efforts can ensure that policies and
programmes are conducive to introducing tenofovir gel if
and when its effectiveness is established.
Introduction of tenofovir gel will, however, have to overcome certain challenges including convincing the DCGI
of its potential benefits in a larger public health context.
Clear findings from the ongoing FACTS 001 trial and
approval by drug licensing authorities in other countries
will be needed to waive the requirement for conducting
Program and Policy Considerations for Tenofovir Gel in India: An Overview ı 7

another trial in India. Post-approval, pilot and operational studies will also be important to understand user
perspectives around tenofovir gel in both general populations and female sex workers. Finally, studies demonstrating the feasibility and impact of adding tenofovir gel
to the package of prevention services will be necessary to
inform decision making and programming approaches.
The overall policy context reflects that India has the political commitment, legal environment, and administrative
structures and guidelines to support introduction of new
products and technologies to address the HIV epidemic. It also has a proven ability to promote new products
through social marketing partnerships. At the same time,
the only programme exclusively focusing on women is the
female condom programme and there has been limited
progress in integrating HIV and reproductive health services. Ultimately, careful analysis will be needed to weigh
whether the challenges and costs associated with tenofovir gel introduction offer sufficient benefit in the context of
India’s HIV epidemic and response.
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